Codice QR

Polyclonal Regulatory T Cell Manufacturing Under cGMP: A Decade of Experience

We report on manufacturing outcomes for 41 autologous polyclonal regulatory T cell (PolyTreg) products for 7 different Phase 1 clinical trials over a 10-year period (2011-2020). Data on patient characteristics, manufacturing parameters, and manufacturing outcomes were collected from manufacturing ba...

Descrizione completa

Salvato in:
Autori principali: Joanna Balcerek, Brian R. Shy, Amy L. Putnam, Lisa M. Masiello, Angela Lares, Florinna Dekovic, Luis Acevedo, Michael R. Lee, Vinh Nguyen, Weihong Liu, Sreenivasan Paruthiyil, Jingying Xu, Ashley S. Leinbach, Jeffrey A. Bluestone, Qizhi Tang, Jonathan H. Esensten
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2021-11-01
Serie:Frontiers in Immunology
Soggetti:
regulatory T cell manufacturing
cGMP
ex vivo expansion
cellular therapy
regulatory T cells
Accesso online:https://www.frontiersin.org/articles/10.3389/fimmu.2021.744763/full
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi